Pemazyre (pemigatinib)

Search documents
Knight Therapeutics Reports First Quarter 2025 Results
Globenewswireยท 2025-05-08 11:30
Financial Results - Revenues for Q1-25 were $88,076, an increase of $1,472 or 2% compared to Q1-24, driven by growth in key promoted products, partially offset by declines in mature products and currency depreciation in select LATAM countries [7][13] - Gross margin decreased to $34,866 or 40% of revenues from $41,699 or 48% in the same period last year, primarily due to hyperinflation accounting in Argentina [7][19] - Operating loss was $5,537 compared to an operating income of $2,660 in Q1-24 [11][25] - Net income was $2,185, a significant improvement from a net loss of $4,546 in the prior year [25] - Adjusted revenues were $87,979, reflecting a 3% increase, and $6,631 or 8% on a constant currency basis [7][13] Corporate Developments - The company entered into an asset purchase agreement to acquire the Paladin business for $100,000, with an additional $20,000 for inventory, and potential future payments of up to $15,000 based on sales milestones [7][36] - A working capital line of credit of USD 40,000 was obtained from Citibank, with USD 35,000 withdrawn [6][37] - The company in-licensed Onicit IV for distribution in Mexico, Brazil, and select LATAM countries, and submitted Tavalisse for ANMAT approval in Argentina [8][33][35] Shareholder Updates - Shareholders re-elected members to the Board of Directors, including Jonathan Ross Goodman and Samira Sakhia [9] Financial Outlook - The company reaffirmed its financial guidance for 2025, expecting revenues between $390 million to $405 million and adjusted EBITDA to be approximately 13% of revenues [38]